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The main proteinase (Mpro) of the severe acute respi-
ratory syndrome (SARS) coronavirus is a principal
target for the design of anticoronaviral compounds.
Benzotriazole esters have been reported as potent
nonpeptidic inhibitors of the enzyme, but their exact
mechanism of action remains unclear. Here we pres-
ent crystal structures of SARS-CoV Mpro, the active-
site cysteine of which has been acylated by benzo-
triazole esters that act as suicide inhibitors. In one
of the structures, the thioester product has been
hydrolyzed and benzoic acid is observed to bind to
the hydrophobic S2 pocket. This structure also fea-
tures the enzyme with a shortened N-terminal seg-
ment (‘‘amputated N finger’’). The results further the
understanding of the important role of the N finger
for catalysis as well as the design of benzotriazole
inhibitors with improved specificity.
INTRODUCTION
The global 2003 outbreak of the highly infectious severe acute
respiratory syndrome (SARS) was caused by a new human coro-
navirus, SARS coronavirus (SARS-CoV) (Ksiazek et al., 2003;
Drosten et al., 2003; Peiris et al., 2003). Spreading from southern
China, the disease was responsible for the death of about 10% of
those infected (Stockman et al., 2006). Since 2003 there have
been two isolated mini-outbreaks in China, but they have been
contained in their early stages. These cases remind us of the
lingering danger to human health represented by SARS-CoV
as well as other coronaviruses, and the need for effective anti-
coronaviral therapeutics. Since the global SARS outbreak, two
new coronaviruses infecting humans have been discovered
(van der Hoek et al., 2004; Fouchier et al., 2004; Woo et al.,
2005). HCoV NL63, a coronavirus associated with croup (Chiu
et al., 2005), appears to be the most widespread member of
the entire family. It is the causative agent of up to 10% of all re-
spiratory diseases (Pyrc et al., 2006 and references therein). De-
tected in 13 patients in Hong Kong, HCoV HKU1 is a coronavirus
associated with relatively mild, community-acquired pneumonia
characterized by fever, running nose, and cough (Lau et al.,
2006), although a subtype of HKU1 causing a severe obstructiveChemistry & Biologpneumonia was recently identified (Kupfer et al., 2007). Two
other human coronaviruses, HCoV 229E and OC43, have been
known for decades, and are believed to cause mild upper respi-
ratory tract illnesses, including the common cold (McIntosh
et al., 1967). Furthermore, HCoV OC43 has also been reported
to have a high prevalence in the brains of multiple sclerosis
patients (Arbour et al., 2000).
Coronaviruses are enveloped, positive-sense RNA viruses.
Their large single-stranded RNA genome ranges from 27 to
31 kb (29.7 kb for SARS-CoV) and encodes several structural
and auxiliary proteins as well as two large overlapping polypro-
teins, pp1a (replicase 1a, 486 kDa for SARS-CoV) and pp1ab
(replicase 1ab, 790 kDa) (Thiel et al., 2003). These polyproteins
are subsequently cleaved to give rise to the individual nonstruc-
tural proteins essential for building the viral replicase complex.
In most coronaviruses, this maturation process is performed by
extensive proteolytic processing by three cysteine peptidases.
There are two papain-like proteinases (PLpro) that are responsible
for acting on three cleavage sites near the N terminus of the poly-
proteins (Ziebuhr et al., 1995), and the main proteinase or Mpro
(also called ‘‘3C-like protease’’ or 3CLpro), which is necessary
for cleaving at no less than 11 conserved sites containing a large
hydrophobic residue (preferably Leu) in the P2 position, a Gln in
the P1 position, and a small aliphatic amino acid residue (Ser,
Gly, Ala) in the P10 position (Ziebuhr et al., 2000; Hegyi and Zie-
buhr, 2002; Anand et al., 2003). In contrast to othercoronaviruses,
the SARS-CoV genome encodes only one PLpro in addition to the
Mpro. Besides being involved in the processing of the polypro-
teins, the PLpro has a second function as a deubiquitinating en-
zyme (Barretto et al., 2005; Lindner et al., 2005). Because of its
pivotal role in viral replication, the 33.8 kDa main proteinase has
become the prime target in the development of inhibitors directed
at SARS-CoV and other coronaviruses (Anand et al., 2003, 2005).
So far, the crystal structures of the main proteinases of four
coronaviruses have been determined: transmissible gastroen-
teritis virus (TGEV) (Anand et al., 2002), HCoV 229E (Anand et al.,
2003), SARS-CoV (Yang et al., 2003; Tan et al., 2005; Xu et al.,
2005; Xue et al., 2007), and infectious bronchitis virus (IBV)
(Xue et al., 2008). Except for IBV, the enzyme is a homodimer,
and this is the quaternary structure observed in solution as well
(Anand et al., 2002; Fan et al., 2004; Hsu et al., 2005a). In fact,
it has been proposed that dimerization is essential for catalytic
activity because the very amino terminus (‘‘N finger’’) of one sub-
unit is involved in organizing the substrate-binding pocket of the
other (Anand et al., 2002; Yang et al., 2003; Tan et al., 2005).y 15, 597–606, June 2008 ª2008 Elsevier Ltd All rights reserved 597
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domains. Domains I (residues 1–101) and II (residues 102–184)
each consist of an antiparallel b barrel; taken together, domains
I and II resemble the structure of chymotrypsin-like serine pro-
teinases (Anand et al., 2002, 2003; Yang et al., 2003; Tsukada
and Blow, 1985). The active site of the Mpro is located in the
interface between the two domains and consists of a Cys-His
catalytic dyad, in which the cysteine acts as the nucleophile in
the proteolytic cleavage reaction (Anand et al., 2002, 2003;
Yang et al., 2003). Connected by a long loop (residues 185–
200) to domain II, domain III is all-helical and not only involved,
to some extent, in dimer formation but also in placing the N finger
next to the substrate-binding site of the other monomer. In the
active conformation of the protein, the individual binding pockets
for the respective amino acid residues of the substrate are
accessible and the oxyanion loop (residues 138–145) has the
correct shape to donate two hydrogen bonds from main-chain
amides to stabilize the tetrahedral transition state of the proteol-
ysis reaction. The two monomers in the dimer are arranged
perpendicular to each other (Figure 1; Yang et al., 2003).
A number of crystal structures with small-molecule inhibitors
bound to the coronavirus Mpro have been reported. Most of these
compounds are peptide analogs derived from the substrate
cleavage consensus sequence, such as peptidyl chloromethyl
ketones (Anand et al., 2003; Yang et al., 2003), vinylogous alkyl
ester derivatives serving as Michael acceptors (Yang et al.,
2005), aza-peptide epoxides (Lee et al., 2005, 2007), or a,b-ep-
oxiketones (Goetz et al., 2007). Peptidyl aldehydes have been
described as reversible inhibitors (Al-Gharabli et al., 2006;
Figure 1. Dimer of the SARS CoV Mpro
Ribbon diagram and surface representation of the dimeric SARS-CoV Mpro
(protomer A in blue, protomer B in light orange). The catalytic dyad residues
(Cys145 and His41) in both monomers colored by atom (yellow, carbon; red,
oxygen; blue, nitrogen; green, sulfur). The N finger (residues 1–7) is colored
magenta for monomer A and green for monomer B. The very N terminus is
marked by a sphere. It interacts with residue Glu166 of the opposing mono-
mer. The oxyanion loop is colored red for monomer A and dark brown for
monomer B.598 Chemistry & Biology 15, 597–606, June 2008 ª2008 Elsevier LtdSchmidt et al., 2008). Also, structure-based virtual screening
approaches have led to the discovery of a number of nonpeptidic
inhibitors (Wu et al., 2004; Bacha et al., 2004; Chen et al., 2005b;
Kaeppler et al., 2005; Tsai et al., 2006), but until now, only a few
crystal structures of such complexes with the protease have
been reported (e.g., Lu et al., 2006).
In the early stages of the 2003 SARS outbreak, one of the first
drugs tried for the treatment of patients was ribavirin, an antiviral
drug commonly used against a number of DNA and RNA viruses
(Sidwell et al., 1972), but this proved to be unsuccessful (Stock-
man et al., 2006; Knowles et al., 2003). Left with few other
options, physicians also tested HIV proteinase inhibitors (Stock-
man et al., 2006), and Wu et al. (2006) found that one of them,
lopinavir, targeted SARS-CoV Mpro with an IC50 of z50 mM. In
their search for derivatives of lopinavir with an improved inhibi-
tory action toward Mpro, Wu et al. (2006) noticed by serendipity
that the intermediate benzotriazole esters occurring during the
synthesis of these derivatives were better inhibitors of the
enzyme than the final products (see also Hilgenfeld and Pumpor,
2006). These benzotriazole esters are the result of the activation
of carboxylic acids by 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetra-
methyluronium hexafluorophosphate (HBTU), which was used
as a coupling reagent in the synthesis of the lopinavir-like mole-
cules. Wu et al. (2006) reported Ki = 7.5 nM and kinact (=k3) =
0.0011 s1 for the best of these inhibitors and suggested, on
the basis of mass spectrometric analyses, that the benzotriazole
esters irreversibly acylate the active-site Cys145. However, even
though these Ki values are among the lowest for any inhibitor of
the SARS-CoV Mpro described so far, Wu et al. (2006) also re-
ported that full inhibition of the enzyme could not be achieved.
Also, upon replacement of the ester oxygen by a methylene
group, the inhibitors bound noncovalently to the enzyme, with
Ki values in the micromolar range (Wu et al., 2006). Such a mech-
anism might also apply, to some extent, to the benzotriazole
esters themselves, perhaps explaining the incomplete inhibition
reported by Wu et al. (2006). Because of these uncertainties, we
wanted to visualize the binding mode of benzotriazole esters to
the SARS-CoV main proteinase, and have determined the crystal
structures of the enzyme after incubation with two such
compounds, 1-(benzoyloxy)-benzotriazole (compound XP-27)
and 1-(4-dimethylaminobenzoyloxy)-benzotriazole (compound
XP-59) (see Figure 2).
RESULTS AND DISCUSSION
Chain Termini of the SARS-CoV Mpro Influence
Catalytic Activity
Two different gene constructs coding for the SARS-CoV main
proteinase were used in this study. One of them ([DSer1]/
C-His6) has the last two residues at the C terminus of the protein
(Phe305 and Gln306) replaced by a hexahistidine tag, while the
codon for the N-terminal serine has been replaced by the start
codon, AUG. As we can demonstrate by Edman degradation
(not shown), the corresponding formylmethionine residue was
cleaved off during synthesis in Escherichia coli, most probably
by methionyl-aminopeptidase (Hirel et al., 1989), creating
D(Ser1)/C-His6 M
pro. The other construct (‘‘authentic Mpro’’) car-
ries an N-terminal GST-AVLQ tag that is autocleaved by the pro-
tease itself, and a C-terminal GP-H6 tag which can be removedAll rights reserved
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possesses the authentic N and C termini (Xue et al., 2007). The
difference in enzymatic activity and dimer stability between
the two constructs illustrates the importance of an intact
N terminus (N finger). The kcat/KM of the (DSer1)/C-His6 protein,
determined by using an HPLC-based assay with the pentadeca-
peptide SWTSAVLQYSGFRKWA as a substrate, was 61.9
(±1.5) mM1min1 (Tan et al., 2005). Using a FRET-based assay
with a fluorogenic peptide substrate (Dabcyl-KTSAVLQY
SGFRKME-Edans), this value was 167.9 mM1min1. The KD
value for the monomer-dimer equilibrium of this enzyme species
was estimated at z250 nM by using the method of Kuo et al.
(2004), much lower than the values derived for a similar construct
by Graziano et al. (2006) from small-angle scattering and chem-
ical crosslinking. Accordingly, the fraction of catalytically active
(DSer1)/C-His6 dimers at the enzyme concentration used in the
assays (1.0 mM with respect to monomers) is about 0.8, and
the kcat/KM of this enzyme species has to be corrected to
z209 mM1min1. The Mpro with the authentic chain termini,
however, is significantly more active under the same circum-
stances and has a kcat/KM value of 502.3 mM
1min1. For the
latter enzyme, the KD value for dimer dissociation was estimated
to be significantly lower than 100 nM, in agreement with most
reports in the literature (Kuo et al., 2004; Hsu et al., 2005b).
This would indicate that > > 90% of the authentic Mpro molecules
exist as dimers at the concentration of 1.0 mM (with respect to
monomers) used in the assays. Occasionally, much higher KD
values have been reported for SARS-CoV Mpro dimer dissocia-
tion in the literature (e.g., Fan et al., 2004; Chen et al., 2005a),
but in most of these cases, the enzyme did not have authentic
chain termini.
For the authentic enzyme, we determined KM = 2.2 mM and
kcat = 1105 min
1, whereas for (DSer1)/C-His6, the respective
values were 0.24 mM and 40.3 min1 (prior to correction for
dimer dissociation; see above). Thus, the authentic enzyme,
although displaying a 10-fold larger KM value, exhibited a 27-
fold higher activity than (DSer1)/C-His6. The crystal structures
presented below provide an explanation for this observation.
Kinetic Data for the Benzotriazole Inhibitors
We found the benzotriazole derivatives to be potent inhibitors of
SARS-CoV Mpro, capable of inhibiting half of the authentic
enzyme activity at low micromolar concentrations (<5 mM and
0.1 mM for XP-27 and XP-59, respectively), as determined using
the fluorogenic peptide cleavage assay. Under the assumption
that the inhibitors act as suicide substrates by covalently binding
to the proteinase, a description of the compounds requires
determination of both the equilibrium binding constant Ki and
the inactivation rate constant (for covalent bond formation)
k3 (=kinact), according to the following scheme (Scheme I, Equa-
tion VIII.127 of Dixon and Webb, 1979):
In competition with the fluorescent peptide substrate (S), the
inhibitor initially forms a Michaelis complex with the proteinase,
which subsequently undergoes a nucleophilic attack by
Cys145 onto the ester bond, leading to the formation of a cova-
lent enzyme-inhibitor product (see Figure 2 for chemical formu-
las and reaction mechanism). The leaving group of the reaction
is 1-hydroxybenzotriazole. For the inhibitor XP-59, the Ki and
k3 values were determined as 1.38 mM and 0.013 s
1, respec-
tively. At an inhibitor concentration of 1.3 mM, approximately
97% inhibition of the enzyme was achieved. For the inhibitor
XP-27, the exact determination of the inhibition constant proved
difficult because of the inherent instability of this compound. UV
absorption of XP-27 decreased in anhydrous dimethyl sulfoxide
(DMSO) over time, even in the absence of enzyme, and this pro-
cess was significantly enhanced by addition of a few microliters
of water. Addition of XP-27 to the enzyme led to rapid inactiva-
tion, but after about 3–4 min, the enzyme activity started to re-
cover (Figure 3A). A possible reason for this behavior is that
the rather instable thioester product may have been partially
hydrolyzed. As we shall see below, our crystal structure of the
enzyme acylated by XP-27 provides an explanation for this ob-
servation. In contrast to XP-27 and its thioester product with
the enzyme, XP-59 and its covalent Mpro adduct were more sta-
ble, because the electron-donating nature of the p-dimethyla-
mino group decreased the electrophilicity of the carbonyl C
atom. The inhibition curve (fluorescence versus time) of XP-59
displayed the expected hyperbolic shape (Figure 3B).
Wu et al. (2006) reported a Ki value of 17.4 nM and a k3 of
0.0013 s1 for XP-59 (their compound 4). We have no immediate
explanation for the discrepancy by a factor of 80 between the Ki
value reported by these authors and our findings, nor for the fac-
tor of 10 between their and our k3 values. We also do not know
whether the kcat/KM value of their enzyme preparation is compa-
rable to ours.
Binding of 1-(Benzoyloxy)-Benzotriazole (Compound
XP-27) to SARS-CoV Mpro (Complex 1)
Complex 1 was obtained by soaking crystals of (DSer1/C-His6)-
SARS-CoV Mpro at pH 6.5 with 5 mM 1-(benzoyloxy)-benzotria-
zole (XP-27). The plate-like crystals displayed space group P21
Figure 2. Chemical Formulas and Reaction
Mechanism
Formulas for compounds XP-27 (X = H) and XP-59
(X = [CH3]2N) and proposed reaction mechanism
(Wu et al., 2006).Chemistry & Biology 15, 597–606, June 2008 ª2008 Elsevier Ltd All rights reserved 599
Chemistry & Biology
SARS-CoV Mpro Inactivated by Benzotriazole EstersFigure 3. Inhibition Kinetics of Benzotria-
zole Esters
Inhibition kinetics of benzotriazole esters XP-27 (A)
and XP-59 (B). The graphs show the fluorescence
(in arbitrary units) created by substrate cleavage
as a function of time. For inhibitor XP-27, the curve
initially reaches a plateau, but after about 3–4 min,
enzymatic activity seems to be restored (A).
For XP-59, the expected hyperbolic curve is
observed (B).(Table 1) and contained one Mpro dimer in the asymmetric unit.
One monomer of the dimer (protomer A) was found to be in the
active conformation, whereas the other exhibits an inactive con-
formation in which the loop forming the oxyanion hole (residues
138–145) has a catalytically incompetent shape. This has previ-
ously been observed in other SARS-CoV Mpro structures when
the crystals had been grown at pH 6.0–6.5, and we have postu-
lated that the inactive form in the dimer arises when a histidine
residue (His163) at the bottom of the S1 specificity pocket is pro-
tonated at low pH, leading to a reorientation of Glu166 and to
the collapse of both the S1 pocket and the oxyanion hole
(Yang et al., 2003; Tan et al., 2005; Anand et al., 2005; see, for
instance, Protein Data Bank [PDB] ID code: 1UJ1).
Table 1. Statistics of Data Collection and Processing, and
Crystallographic Refinement
XP-27 XP-59
Data Collection
Space group P21 C2
Unit cell dimensions
a (A˚) 52.23 108.27
b (A˚) 97.76 81.97
c (A˚) 67.71 53.42
b () 103.01 104.3
Wavelength (A˚) 0.8157 0.8080
Resolution range (A˚) 40–2.25 65–1.95
Outer shell (A˚) 2.34–2.25 2.02–1.95
Unique reflections 31,491 30,270
Mean redundancya 3.2 (3.2) 3.4 (3.4)
Completeness (%)a 99.7 (100.0) 97.4 (96.8)
Rmerge (%)
a,b 7.3 (46.6) 12.3 (44.5)
I/s(I) 12.9 (1.91) 12.8 (2.49)
Refinement
R factor (%)c 18.30 16.48
Free R factor (%)d 25.59 21.01
Root-mean-square deviations from ideality
Bonds (A˚) 0.016 0.016
Angles () 1.57 1.64
a Values in parentheses are for the highest resolution shell.
b Rmerge =
P
hkl
P
ijI < I >j/
P
hkl
P
i I3 100%, where I and < I > are the ith
observed intensity and average intensity of the reflection hkl, respec-
tively.
c R factor =
P
hkljjFobsj  jFcalcjj/
P
hkljFobsj 3 100%.
d Free R factor =
P
hkl < TjjFobsj  jFcalcjj/
P
hkl < TjFobsj 3 100%, where
hkl < T represents the test data set of 5% of the diffraction data.600 Chemistry & Biology 15, 597–606, June 2008 ª2008 Elsevier LtdWhen examining the electron density for monomer B, extra
density was seen connected to the active-site Cys145 into which
we could model a covalently bound benzoyl ester, with an occu-
pancy of 70% (Figure 4A). The benzene ring of the inhibitor lies
like a lid on top of the entrance to the S1 pocket and pushes
away the Glu166 side chain, which is originally (30% occupancy
remaining for this conformation) blocking the pocket. The O32
atom of the reoriented Glu166 now makes a hydrogen bond to
the N32 atom of His172 (2.54 A˚), just like in the active conforma-
tion (Tan et al., 2005). Presumably, the highly reactive and rela-
tively small inhibitor induces this conformation upon binding,
but its steric demands on the oxyanion loop are too limited to
force this segment into the active conformation. The benzene
ring of the covalently bound inhibitor makes van der Waals
contacts with the rim of the collapsed oxyanion loop (Ca atoms
of Asn142 and Gly143).
Surprisingly, the immediate active site of monomer A is empty
and contains no electron density for a covalently bound product.
However, in the hydrophobic S2 specificity pocket, we found
clear difference density (>4s) for a benzoic acid molecule. The
molecule is sandwiched between the side chains of Met49 and
Met165. The latter adopts two conformations, one of which (oc-
cupancy 50%) is not compatible with the presence of benzoic
acid at this site. The occupancy of the benzoic acid molecule
was fixed at 30%. The observation of this molecule in the S2
site immediately raises the question as to which mechanism
was at work here. We assume that the thioester formed between
the benzoyl group and Cys145 (with 1-hydroxybenzotriazole be-
ing the leaving group) is attacked by one of the numerous water
molecules in the substrate-binding site. This results in the pro-
duction of benzoic acid and restoration of the free active-site
cysteine. Because of its overall hydrophobicity, the benzoic
acid then binds to the nearby S2 pocket (Figure 4B). This inter-
pretation is in full agreement with the observed biphasic kinetics
for XP-27 (Figure 3A). However, even though benzoic acid itself
is not an inhibitor of the enzyme up to mM concentrations (data
not shown), we cannot exclude that the compound bound to
the S2 pocket might originate from degradation of free XP-27
in solution over the time of the crystal-soaking experiment. In
any case, our findings help explain the observation of Wu et al.
(2006) that their benzotriazole inhibitors, although displaying
nanomolar Ki values, did not lead to complete inhibition of the
enzyme.
If hydrolysis of the enzyme-bound thioester occurs with
XP-27, why then only in the A monomer? Only in this molecule
is the oxyanion loop in the correct conformation to stabilize the
tetrahedral intermediate of the hydrolysis reaction. In the B
monomer, this loop is in the catalytically incompetentAll rights reserved
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SARS-CoV Mpro Inactivated by Benzotriazole EstersFigure 4. Active-Site Environment of the
SARS-CoV Mpro Reacted with 1-(Benzoy-
loxy)-Benzotriazole
Active-site environment of the SARS-CoV Mpro
reacted with 1-(benzoyloxy)-benzotriazole (XP-
27), with corresponding 2Fo  Fc electron density
map (contoured at 1s above the mean).
(A) Monomer B with Cys145 acylated by the
1-(benzoyloxy) moiety (70% occupancy; atom
colors), which covers the S1 specificity pocket.
An Fo  Fc omit map (green), contoured at 2.75s
above the mean, is shown for the inhibitor moiety.
Glu166 (red) has a double conformation, one of
which exists in the 30% of the molecules that do
not have the active-site cysteine acylated. Met49
and Met165 (double conformation) (orange) line the S2 specificity pocket. His163 and His172 are colored in magenta. The catalytic dyad residues (Cys145
and His41) are colored by atom (yellow, carbon; red, oxygen; blue, nitrogen; green, sulfur). Loop 138–145 is in an inactive conformation (Phe140 turned away
from His163) and colored gray.
(B) Monomer A represents the structure after hydrolysis of the thioester. The resulting benzoic acid molecule (atom colors; Fo  Fc omit map, contoured at 2.75s,
shown in green) has entered the S2 pocket and is sandwiched between Met49 and Met165 (orange). The latter has two conformations, one of which exists only in
the 50% of the molecules that do not have the benzoic acid bound. The oxyanion loop (gray) is in an active conformation, with Phe140 stacking against His163
(magenta). The 2Fo  Fc electron density maps (blue) are contoured at 1s above the mean.conformation and, therefore, the thioester adduct remains rela-
tively stable (even though the occupancy is only 70%).
Amputation of the N Finger in (DSer1)/C-His6 M
pro Leads
to Local Structural Changes
Apart from some small differences, mostly in flexible loops at the
periphery of the protein and at the C terminus, the dimeric struc-
tures seen in the enzyme modified by XP-27 and the original
1UJ1 dimer (Yang et al., 2003) overlay quite well. The overall
root-mean-square deviation for 577 out of 600 Ca atoms is
0.36 A˚. Interestingly, we found electron density for three
DMSO molecules, which must originate from the DMSO used
to dissolve the inhibitor in the crystal-soaking experiment. One
of them fills a hole at the site where the N fingers of the two poly-
peptide chains approach each other, near the carbonyl groups of
the Lys5 residues of both the A and the B monomer, that is, more
or less on the noncrystallographic two-fold axis of symmetry
(near the position where the magenta and green polypeptide
segments meet in Figure 1). This site could be of interest for
designing dimerization inhibitors. The two remaining DMSO
molecules fill the space between the Mpro dimers adjacent to
the crystal contacts, next to the AspB244.His#A134 (DMSO2)
and the GlnA256.Trp#A31/Ala#A70 (DMSO3) contacts (# marks
a residue in a symmetry-related dimer).
Because of the cloning procedure used in the present study,
the N-terminal serine has been replaced by a formylmethionine
which, favored by the penultimate residue being a glycine, was
cleaved off during synthesis in E. coli (Hirel et al., 1989). This
causes the ‘‘amputated N finger’’ (residues 2–7, DSer1) to be-
come more flexible. As a result, residues Gly2 and Phe3 in
both monomers A and B have flipped their orientation such
that the N terminus of Gly2 is now, at least in protomer B, hydro-
gen bonded to the Sg atom of Cys300 (domain III) of the parent
monomer (at 2.39 A˚ in protomer B, 4.50 A˚ in protomer A) and the
N finger can no longer stabilize the loop (residues 138–145) form-
ing the oxyanion hole of the other monomer. This is observed in
monomer B, where the oxyanion loop is in a collapsed conforma-
tion as discussed before. Yet, in monomer A, this loop is in theChemistry & Biologycatalytically competent form although the main-chain conforma-
tion of Phe140 is no longer stabilized by the N finger of monomer
B. But the phenyl ring of this residue is still embedded in a hydro-
phobic pocket consisting of Val114, Ala116, Tyr126, Tyr161,
His163, and His172. The lack of an intact N finger, however,
does make the loop 138–145 more flexible. This is reflected in
the B factors of the main-chain atoms of the loop in monomer
A (44.4–74.0 A˚2, with an average of 64.3 A˚2), which are higher
than the average B factor of the entire main chain (40.4 A˚2).
This situation is comparable to the B factors observed in the
loop 138–145 of the B monomer (47.1–77.8 A˚2, with an average
of 67.9 A˚2; the average B factor for the entire main chain is
41.7 A˚2). The high flexibility of the oxyanion-binding loop explains
the fact that kcat for the enzyme with the amputated N finger is
significantly lower (40.3 min1) than for the authentic Mpro
(1105 min1). On the other hand, deletion of the N-terminal serine
may create more space in the substrate-binding site, hence the
lower KM for the (DSer1)/C-His6 enzyme.
We have shown in this work that deletion of Ser1, Phe305, and
Gln306, plus the C-terminal attachment of a hexahistidine tag
(not seen in the electron density maps), reduces enzymatic activ-
ity (kcat/KM) byz59%. In another study, Hsu et al. (2005a) have
shown that a deletion of the three N-terminal amino acid residues
reduces the enzyme’s activity by a mere 24%, whereas the
fourth residue, arginine, is absolutely essential for catalytic activ-
ity and important for the formation of the dimer. In agreement
with this, we previously reported almost total inactivation of the
homologous main proteinase from TGEV upon removal of five
residues from the N terminus (Anand et al., 2002). In another re-
port, removal of the seven N-terminal residues abolishes the
enzymatic activity of the main proteinase almost completely,
but does not seem to have much influence on dimer formation
(Chen et al., 2005a) (however, the enzyme used in this study
had both N- and C-terminal extensions). It has been suggested
by molecular dynamics simulations that a different dimer could
form under these conditions, which involves much more elabo-
rate contact between domains III of the monomers (Chen et al.,
2005a). This would be in agreement with the observed15, 597–606, June 2008 ª2008 Elsevier Ltd All rights reserved 601
Chemistry & Biology
SARS-CoV Mpro Inactivated by Benzotriazole EstersFigure 5. Active-Site Environment of the
SARS-CoVMpro Reacted with 1-(4-Dimethy-
laminobenzoyloxy)-Benzotriazole
Active-site environment of the SARS-CoV Mpro re-
acted with 1-(4-dimethylaminobenzoyloxy)-ben-
zotriazole (XP-59), with corresponding 2Fo  Fc
electron density map (contoured at 1s above the
mean).
(A) Cys145 is acylated by the 1-(4-dimethylamino-
benzoyloxy) moiety (atom colors; color code as in
Figure 4), which extends toward the S2 specificity
pocket. An Fo  Fc omit map (green), contoured at
2.75s above the mean, is overlaid onto the inhibi-
tor moiety. Met49 and Met165 (orange) line the S2
specificity pocket. His163 and His172 are colored
in magenta. The catalytic dyad residues (Cys145
and His41) are colored by atom. Loop 138–145 is
in an active conformation and colored gray. The 2Fo  Fc electron density map is contoured at 1s above the mean.
(B) Comparison of the active site of the free enzyme (light orange) with the 1-(4-dimethylamino)-benzoyl thioester (gray). 2Fo  Fc electron density (contoured
at 1s above the mean) is shown for the thioester and His41. The latter has rotated in comparison to the free enzyme and is now stacking against the aromatic
moiety of the inhibitor.dimerization of isolated domain III of SARS-CoV Mpro (Shi et al.,
2004). Although the N-terminal residues obviously have an effect
on the stability of an intact substrate-binding site, the catalytic
activity of the Mpro is probably mainly controlled by the proton-
ation states of the two histidine residues, His163 and His172,
in the substrate-binding site. Molecular dynamics calculations
performed on the Mpro dimer have emphasized the role played
by these two histidines in maintaining the correct conformation
of the substrate-binding site (Tan et al., 2005).
Binding of 1-(4-Dimethylaminobenzoyloxy)-
Benzotriazole (XP-59) to SARS-CoV Mpro (Complex 2)
Complex 2 was obtained by cocrystallization. SARS-CoV Mpro
(with authentic chain termini) was incubated for 2 hr at 25C
with a 7-fold excess of 1-(4-dimethylaminobenzoyloxy)-benzo-
triazole (compound XP-59), and crystal growth was initiated by
microseeding using crushed crystals of the free enzyme. Small
block-sized (0.2 mm 3 0.1 mm 3 0.1 mm) crystals appeared
overnight and displayed monoclinic space group C2 (Table 1),
isomorphous to the crystals of the free enzyme (Xue et al.,
2007). These crystals, grown at pH 6.0, have one monomer in
the asymmetric unit, which has the substrate-binding site in the
active conformation. Formed by the crystallographic two-fold
axis from the monomer, the dimer is very similar to the one in
the P21 crystal structures, except for the oxyanion loops of
both monomers being in the active conformation. The largest
differences occur between the C termini of the monomers and
between the oxyanion loops of monomer B, which is in the col-
lapsed conformation in the P21 crystal structure. The C terminus
in the C2 crystal structure is completely visible and extends in a
direction different from the apparently flexible C terminus in the
P21 crystal structure. The root-mean-square deviation for 584
out of 603 Ca atoms with the dimer observed in space group
P21 (Yang et al., 2003; PDB ID code: 1UJ1) is 0.83 A˚, whereas
this value is only 0.23 A˚ (297 out of 306 Ca pairs) for the compar-
ison with the enzyme with authentic chain termini that was
crystallized in space group C2 (Xue et al., 2007).
Upon inspection of the active site of the Mpro-inhibitor com-
plex, clear electron density was observed for the 1-(4-dimethyla-602 Chemistry & Biology 15, 597–606, June 2008 ª2008 Elsevier Ltmino)-benzoyl moiety covalently bound to Cys145 (Figure 5A).
Surprisingly, the side chain of the other catalytic dyad residue
His41 has undergone a rotation away from Cys145 (Figure 5B).
It is now stacked against the phenyl ring of the inhibitor, making
good p-p interactions (distance between the planes is 3.4 A˚).
The S1-binding pocket is not occupied by the inhibitor. Instead,
a chain of three water molecules with well-defined density con-
nects the His163 N32 atom at the bottom of the S1 specificity
site with the side chains of Glu166 (O31) and Asn142 (Od1).
The dimethylamino moiety of the inhibitor is situated be-
tween the side chains of Met49 and Met165, where it partly
occupies the S2 specificity pocket. It is also involved in van
der Waals interactions with the main-chain atoms of residues
Asp187, Arg188, Gln189, and Pro39. A similar binding mode of
the inhibitor to the main proteinase is observed when C2 crystals
of the free enzyme are soaked at pH 7.0 with a 20-fold excess of
compound XP-59 (data not shown). Binding of a substituted
phenyl group to the S2 specificity subsite has also been
observed in other studies (e.g., Goetz et al., 2007).
In the crystal structure of complex 2, the loop 138–145 is being
held in the active conformation by the N finger of the symmetry-
related molecule (distance SerB1 N–PheA140 O: 2.67 A˚) in order
to create the perfect environment for the oxyanion transition
state. The conformation of this loop is quite stable, as can be de-
duced from the B factors of the main-chain atoms of the loop
compared to the overall B factor of the entire main chain (ranging
from 24 to 34 A˚2 with an average of 28.6 A˚2, compared to
31.5 A˚2). Equally, the amino terminus of the N finger is also hydro-
gen bonded to Glu166 O31 (at 2.75 A˚), preventing closure of the
S1 specificity pocket by the Glu166 side chain. This catalytically
competent conformation explains the high kcat (1105 min
1) ob-
served for the authentic enzyme, when compared to the situation
in the enzyme featuring the amputated N finger ([DSer1]/C-His6;
kcat = 40.3 min
1).
Comparison of the crystal structures of the two Mpro-inhibitor
complexes shows that the covalently bound suicide-inhibitor
products are oriented in different directions (cf. Figures 4A and
5A). The benzoyloxy moiety in complex 1 (molecule B) is covering
the S1 specificity pocket (Figure 4A), whereas the dimethylaminod All rights reserved
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SARS-CoV Mpro Inactivated by Benzotriazole Estersgroup in complex 2 is entering the S2-binding site (Figure 5A). In
an attempt to explain how the inhibition can proceed, Wu et al.
(2006) have modeled a number of their benzotriazole inhibitors,
among them XP-59, into the active site of the SARS-CoV Mpro.
In their model of the Michaelis complex, the benzotriazole is
positioned in the oxyanion hole environment and the remainder
of the inhibitor is located in the vicinity of amino acid residues
Thr25, Thr26, His41, Thr45, Ala46, and Met49, leaving the car-
bonyl group of the benzotriazole ester close enough to the Sg
of the active-site Cys145 for a nucleophilic attack to occur.
This orientation of the inhibitor is possible, but then the resulting
covalently bound products have to swing at least 90 around the
covalent bond to occupy an energetically probably more favor-
able niche on top of the S1-binding site or in the S2 pocket in
the two crystal structures, respectively. Because of the rather
small size of the products of suicide inhibition, this should be
possible without serious steric clashes. That structural rear-
rangements must have happened in the enzyme after the reac-
tion with the inhibitor is clear in the crystal structure of Mpro
complexed with the dimethylaminobenzoyloxy moiety (from
compound XP-59) where, first, the oxygen atom proposed to
be stabilized in the oxyanion hole (formed by the main-chain
amides of Gly143 and Cys145) during the transition state of the
reaction is flipped away and makes no specific contacts any-
more and, second, the side chain of the active-site residue
His41 has moved away from its original position to make the
stacking interactions with the inhibitor product as discussed
previously (Figure 5B).
SIGNIFICANCE
Caused by a newly identified coronavirus, SARS-CoV, se-
vere acute respiratory syndrome (SARS) is an emerging dis-
ease that has the capacity to becomeaglobal threat toworld
health because of its rapid transmission. The animal reser-
voir for the virus (most probably bats) is still existent and a
renewed zoonotic transition to man cannot be excluded.
Therefore, efficient drugs are needed in order to be prepared
for a possible future outbreak. The SARS-CoV main protein-
ase (Mpro) plays a central role in the formation of the viral
replicase/transcriptase complex and is thus an ideal target
for the development of suitable drugs.
The structures of complexes of the Mpro resulting from
reaction with two aromatic benzotriazole esters provide
a promising starting point for designing more specific inhib-
itors for the proteinase. Because of their high reactivity, the
inhibitors presented here might not be very selective, al-
though it is encouraging to note that in the entire main
proteinase with its 12 cysteine residues, only the active-site
Cys145 is acylated. Furthermore, Wu et al. (2006) reported
that these compounds are not cell toxic, at least not up to
a concentration of 100 mM. Starting from these lead struc-
tures, the inhibitors can nowbemodified by substituents oc-
cupying the S1 andS2 specificity pockets in order to improve
their potency and specificity. The structures presented here
also demonstrate that electron-donating substituents in the
benzoyl moiety are useful to stabilize the thioester bonds
with the active-site cysteine against hydrolysis. Finally, theChemistry & Biologystructure of the Mpro featuring an amputated N finger (resi-
due Ser1 deleted) explains the reduced catalytic activity of
this species.
EXPERIMENTAL PROCEDURES
Expression and Purification
The C-terminally His6-tagged SARS-CoV M
pro was cloned and overexpressed
in E. coli BL21 (DE3) cells. Plasmid pET-SCoV-Mpro-D305-306(63 His) was
kindly provided by Dr. J. Ziebuhr. In this plasmid, the nucleotides coding for
the C-terminal residues Phe305 and Gln306 have been replaced by a hexahis-
tidine tail, whereas the codon for the N-terminal Ser1 was replaced by a start
codon. Most likely, the resulting N-formylmethionine has posttranslationally
been cleaved off by the methionine-aminopeptidase during expression in
E. coli (Hirel et al., 1989). Edman degradation showed the polypeptide chain
to begin with residue Gly2. The overexpressed protein was purified by
nickel-NTA affinity chromatography followed by a gel-filtration step. Only the
middle fractions of the resulting elution peak were pooled and used for crystal-
lization experiments.
The plasmid coding for SARS-CoV Mpro with authentic N and C termini was
a gift from Prof. Z. Rao (Xue et al., 2007). The plasmid was transformed inE. coli
BL21 (DE3) cells as an N-terminal GST fusion protein with a C-terminal tag of
eight extra residues containing a glycine, a proline, and six histidines (GPH6).
Because of the construction of the plasmid, the GST tag was cleaved off by
autocatalytic processing of the active Mpro. The C-terminally GPH6-tagged
product was subjected to nickel-NTA affinity chromatography and concen-
trated in PreScission cleavage buffer (Walker et al., 1994). The PreScission
protease cleaved off the C-terminal GPH6 tag, producing an authentic
SARS-CoV Mpro. The wild-type protein was further purified using anion-
exchange chromatography (Xue et al., 2007).
Preparation of Benzotriazole Esters
To a stirred solution of 2.5 mmol N-hydroxybenzotriazole and 2.75 mmol
triethylamine in 4 ml dichloromethane (DCM) at room temperature, 2.5 mmol
benzoyl chloride was slowly added. The reaction mixture was stirred for
2 hr, diluted with DCM (20 ml), washed with saturated NaHCO3 solution (2 3
4 ml) and brine (1 3 5 ml), dried over MgSO4, and filtered. The solvent was
removed under reduced pressure and the residue was purified to provide
the desired benzotriazole.
1-(Benzoyloxy)-Benzotriazole (XP-27)
After the reaction mixture had been worked up, the crude product was purified
by column chromatography using diethyl ether:cyclohexane (2:3). 1-(benzoy-
loxy)-benzotriazole was obtained in 91% yield as a white solid. Melting point
74C; ms (ESI) m/z = 239.0 [M]+, 105.0 [C6H5CO]
+.
1-(4-Dimethylaminobenzoyloxy)-Benzotriazole (XP-59)
After the reaction mixture had been worked up, the crude product was recrys-
tallized from hexane:ethyl acetate. 1-(4-dimethylaminobenzoyloxy)-benzotria-
zole was obtained in 80% yield as a slightly yellow solid. Melting point 153C;
ms (ESI) m/z = 869.3 [3M + Na]+, 587.2 [2M + Na]+, 305.1 [M + Na]+.
Enzyme Kinetics
Both a fluorescence-based and an HPLC assay were used to assess the activ-
ity of the SARS-CoV Mpro. The former made use of the fluorogenic peptide sub-
strate Dabcyl-KTSAVLQYSGFRKME-Edans (95% purity; Biosyntan GmbH,
Berlin, Germany), which contains the main proteinase cleavage site (indicated
by the arrow). The enhanced fluorescence due to the cleavage of this substrate
as catalyzed by the enzyme was monitored at 490 nm with excitation at
340 nm, using a Cary Eclipse fluorescence spectrophotometer. The experi-
ments were performed in a buffer consisting of 20 mM Tris-HCl (pH 7.3),
100 mM NaCl, 1 mM EDTA. Kinetic parameters KM and kcat were determined
by initial-rate measurements at 25C. The reaction was initiated by adding
proteinase (final concentration 0.5 mM) to a solution containing different final
concentrations of the fluorogenic peptide (10–40 mM). The initial rates were
converted to enzyme activities (mmol substrate cleaved per s). Kinetic con-
stants were derived by fitting the data to the Michaelis-Menten equation
with the nonlinear regression analysis program SigmaPlot (SigmaPlot 2000,
version 6.00; SPSS, Chicago, IL, USA).15, 597–606, June 2008 ª2008 Elsevier Ltd All rights reserved 603
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Briefly, the substrate used here was the pentadecapeptide SWTSAVLQY
SGFRKWA, which also resembles the cleavage site at the N terminus of the
SARS-CoV Mpro, except for the two tryptophans at either side of the cleavage
site replacing the P7 Ile and theP60 Met residues. The 20ml reaction mixture con-
tained the inhibitor at concentrations varying from 5 to 500 mM, 1.5 mM Mpro
dimer (diluted in 100 mM morpholinoethanesulfonic acid monohydride [MES]
[pH 7.0]), and 250 mM substrate. Inhibitor and Mpro were incubated for 5 min at
room temperature before adding the substrate. The reaction was run for 5 min at
25C, then stopped by adding 5 ml trifluoroacetic acid (0.1%) and put on ice or
stored at 20C. The samples were centrifuged and 80 ml MES buffer (100 mM)
was added. Products and substrate were separated on a reverse-phase HPLC
column (Jupiter 4m Proteo 90A, Phenomenex, Torrance, CA, USA), using a gra-
dient of acetonitrile in 0.1% trifluoroacetic acid. The product and substrate
peaks were detected at 280 nm, and IC50 values were determined.
Inhibition Assay
The fluorescence-based assay was also used for the determination of the
inhibitor constants of the two benzotriazole compounds. These tests were
performed with the untagged, authentic SARS-CoV Mpro. Values of Ki and k3
(see scheme above) were calculated from plots of 1/kobs versus 1/[I] according
to Equation 1 (Equation VIII.129 of Dixon and Webb, 1979):
1
kobs
=
1
k3
+
Ki
k3
$

1+
½S
Km

$
1
½I: (1)
To obtain the observed first-order inhibition rate constant kobs, time-depen-
dent progress curves were fitted to a first-order exponential (Equation 2; equiv-
alent to Equation A10 of Tian and Tsou, 1982, with the addition of D; see
below):
F =

v0
kobs

$

1  expkobs$t+D: (2)
F is the product fluorescence (measured in arbitrary units), v0 is the initial
velocity, t is time, and D is a displacement term to account for the nonzero
emission at the start of data collection.
In the experiment, the Ki and k3 values for the irreversible inhibitors were ob-
tained from reactions initiated by addition of the enzyme (final concentration
0.5 mM) to 20 mM Tris-HCl buffer (pH 7.3) containing 100 mM NaCl, 1 mM
EDTA, 20 mM fluorogenic substrate, and inhibitor. Four different inhibitor
concentrations were tested, in at least 10-fold molar excess over the enzyme
in most cases. Data from the continuous assays were analyzed with the
nonlinear regression analysis program SigmaPlot.
Crystallization of the Complexes
Before crystallization, the C-terminally His6-tagged SARS-CoV M
pro ([DSer1]/
C-His6) was dialyzed against 50 mM Tris-CH3COOH (pH 7.5), 1 mM EDTA,
5 mM DTT and concentrated to 10 mg/ml. The protein was crystallized at
18C by vapor diffusion using hanging drops or sitting drops. The crystalliza-
tion conditions were 5% PEG 10,000, 0.1 M MES (pH 6.5), 3% ethylene glycol,
50 mM ammonium acetate (Lee et al., 2005). Plate-shaped crystals of mono-
clinic form appeared after 3 days to a week, sometimes accompanied by
needles and irregularly shaped crystals, which turned out to belong to the te-
tragonal space group (see Tan et al., 2005). One of the monoclinic crystals
was soaked for 4 days at 18C in the crystallization buffer solution containing
5 mM 1-(benzoyloxy)-benzotriazole (XP-27) and 10% DMSO to increase the
solubility of the inhibitor.
The untagged SARS-CoV Mpro with authentic chain termini, concentrated to
10 mg/ml in 50 mM Tris-HCl (pH 7.5), 40 mM NaCl, 1 mM EDTA, 5 mM DTT,
was incubated for 2 hr at 25C with a 7-fold excess of the inhibitor 1-(4-dime-
thylaminobenzoyloxy)-benzotriazole (XP-59) and solubilized in 8% PEG 6000,
0.1 M MES (pH 6.0), 3% 2-methyl-2,4-pentanediol (MPD). Block-shaped crys-
tals grew overnight at 20C in 6%–8% PEG 6000, 0.1 M MES (pH 6.0), 3%
MPD, after initiation of nucleation by microseeding using crushed C2 crystals
of the free enzyme.
Prior to data collection, crystals obtained from both procedures were trans-
ferred for a couple of seconds to a cryoprotectant solution containing the
crystallization conditions and 30% PEG 400.604 Chemistry & Biology 15, 597–606, June 2008 ª2008 Elsevier LtCrystallographic Data Collection and Processing, and Structure
Elucidation and Refinement
Statistics of data collection, processing, and refinement are summarized in
Table 1. Diffraction data were collected at 100K using monochromatic syn-
chrotron radiation provided by beamlines X11 and X13 (EMBL and Universities
of Hamburg and Lu¨beck, DESY, Hamburg, Germany; wavelength 0.8157 and
0.8080 A˚, respectively). Intensities were measured using a MAR CCD detector.
Indexing, scaling, and merging of data sets were performed using DENZO and
SCALEPACK (Otwinowski and Minor, 1997). Molecular replacement and
refinement were carried out using MOLREP (Vagin and Teplyakov, 1997)
and REFMAC (Murshudov et al., 1997), respectively, as implemented in the
CCP4 suite (CCP4, 1994). Simple bulk scaling in REFMAC was preferred
over Babinet scaling because this procedure better reflected the overall Wilson
B factor. The search model used for molecular replacement was either the
dimer or monomer A of the crystal structure of PDB ID code 1UJ1 for the
data sets of SARS-CoV Mpro complexed with XP-27 or XP-59, respectively.
The computer graphics program Coot, implemented in the CCP4 suite, was
used for interpretation of the electron density maps and model building (Ems-
ley and Cowtan, 2004). The molecular graphics package PyMOL was used to
generate the figures (DeLano, 2002).
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